Stephen Forman - Sep 30, 2024 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
Director
Signature
/s/ Stephen Forman
Stock symbol
LIXT
Transactions as of
Sep 30, 2024
Transactions value $
$0
Form type
4
Date filed
10/29/2024, 05:42 PM
Previous filing
Jul 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +3.86K $0.00 3.86K Sep 30, 2024 Common 3.86K $1.30 Direct F1
holding LIXT Options to Purchase Common Stock 10K Sep 30, 2024 Common 10K $2.37 Direct
holding LIXT Options to Purchase Common Stock 3.02K Sep 30, 2024 Common 3.02K $2.37 Direct
holding LIXT Options to Purchase Common Stock 10K Sep 30, 2024 Common 10K $5.88 Direct
holding LIXT Options to Purchase Common Stock 10K Sep 30, 2024 Common 10K $7.45 Direct
holding LIXT Options to Purchase Common Stock 10K Sep 30, 2024 Common 10K $30.30 Direct
holding LIXT Options to Purchase Common Stock 5K Sep 30, 2024 Common 5K $32.10 Direct
holding LIXT Warrants to Purchase Common Stock 2.11K Sep 30, 2024 Common 2.11K $57.00 By Stephen Forman Living Trust
holding LIXT Options to Purchase Common Stock 833 Sep 30, 2024 Common 833 $9.00 Direct
holding LIXT Options to Purchase Common Stock 833 Sep 30, 2024 Common 833 $66.00 Direct
holding LIXT Warrants to Purchase Common Stock 1.67K Sep 30, 2024 Common 1.67K $60.00 By Stephen Forman Living Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective September 30, 2024, the reporting person was granted stock options to purchase an aggregate of 3,858 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.